Skip to content
value.today
Supernus Pharmaceuticals Inc. logo

Supernus Pharmaceuticals Inc.

Total raised
$30 M
1 round on record
Latest round
$30 M
Jan 2011
First round on record
Jan 2011
Today
Went public
See the company page

Supernus Pharmaceuticals Inc. is listed today as Supernus Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Supernus Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2011$30 MNo. 1$10 to $50 million

Supernus Pharmaceuticals Inc.: Raise no. 1, Jan 2011

Investors in this round

3 investors had bought by the notice of Feb 16, 2012: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Supernus Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
$2,000,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jack A. Khattar · Executive Officer, Director
  • Jones W. Bryan, Ph.D. · Executive Officer
  • Padmanabh P. Bhatt, Ph.D. · Executive Officer
  • Paolo P. Baroldi, M.D., Ph.D. · Executive Officer
  • Russell P. Wilson · Executive Officer
  • Tami T. Martin, R.N., Esq. · Executive Officer
  • Charles W. Newhall, III · Director
  • Frederick M. Hudson · Director
  • John M. Siebert · Director
  • M. James Barrett, Ph.D. · Director
  • Michael B. Sheffery, Ph.D. · Director
  • Michael James Bigham · Director
  • William A. Nuerge · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jack A. Khattar, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 16, 2012. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Supernus Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Qelbree $304.65 million (42%), GOCOVRI $146.82 million (20%), Collaboration revenue (ZURZUVAE) $53 million (7%), APOKYN $47.77 million (7%), Trokendi XR $42.42 million (6%).

    Annual report (SEC XBRL) · Dec 2025

  • Supernus Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2012).

    SEC Form D · Feb 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2012

Products and services#

No products or services of Supernus Pharmaceuticals Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Supernus Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Abingworth Management LTDFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Nea 11 GP, LLCOthernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Nea Partners 11 LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
New Enterprise Associates 11 LPFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Orbimed Capital GP II LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 3 investors.

Largest shareholders today

Institutions holding Supernus Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Supernus Pharmaceuticals Inc.
NameRoleNamed in
Jack A. KhattarExecutive officerFeb 2012
Jones W. Bryan, Ph.D.Executive officerFeb 2012
Padmanabh P. Bhatt, Ph.D.Executive officerFeb 2012
Paolo P. Baroldi, M.D., Ph.D.Executive officerFeb 2012
Russell P. WilsonExecutive officerFeb 2012
Tami T. Martin, R.N., Esq.Executive officerFeb 2012
Charles W. Newhall, IIIDirectorFeb 2012
Frederick M. HudsonDirectorFeb 2012
Jack A. KhattarDirectorFeb 2012
John M. SiebertDirectorFeb 2012
M. James Barrett, Ph.D.DirectorFeb 2012
Michael B. Sheffery, Ph.D.DirectorFeb 2012
Michael James BighamDirectorFeb 2012
William A. NuergeDirectorFeb 2012

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.